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Abstract
Background: Aberrant methylation is a frequent event in oral cancer.
Methods: In order to better characterize these alterations, a search for genes downregulated by aberrant
methylation in oral squamous cell carcinoma (OSCC) was conducted through the mining of ORESTES dataset.
Findings were further validated in OSCC cell lines and patients’ samples and confirmed using TCGA data.
Differentially expressed genes were identified in ORESTES libraries and validated in vitro using RT-PCR in HNSCC
cell-lines and OSCC tumor samples. Further confirmation of these results was performed using mRNA expression
and methylation data from The Cancer Genome Atlas (TCGA) data.
Results: From the set of genes selected for validation, CA3 and FHL1 were downregulated in 60% (12/20) and 75%
(15/20) of OSCC samples, respectively, and in HNSCC cell lines. The treatment of cell lines JHU-13 and FaDu with
the demethylating agent 5'-aza-dC was efficient in restoring CA3 and FHL1 expression. TCGA expression and
methylation data on OSCC confirms the downregulation of these genes in OSCC samples and also suggests that
expression of CA3 and FHL1 is probably regulated by methylation. The downregulation of CA3 and FHL1 observed
in silico was validated in HNSCC cell lines and OSCC samples, showing the feasibility of integrating different
datasets to select differentially expressed genes in silico.
Conclusions: These results showed that the downregulation of CA3 and FHL1 data observed in the ORESTES
libraries was validated in HNSCC cell lines and OSCC samples and in a large cohort of samples from the TCGA
database. Moreover, it suggests that expression of CA3 and FHL1 could probably be regulated by methylation
having an important role the oral carcinogenesis.
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Background
Squamous cell carcinoma (SCC) is the most frequent
histological subtype of oral cavity cancers. This disease
originates from the epithelial tissue that covers the entire
aero digestive tract and accounts for more than 90% of
all malignancies in that anatomical region [1]. This
cancer site is among the most common worldwide and a
major cause of morbidity and mortality [2]. Despite
extensive research and improvements in diagnostic
methods and treatment approaches, the five-year overall
survival rate for oral squamous cell carcinoma (OSCC)
patients have only improved marginally. Investigation of
molecular targets and signaling pathways to design
appropriate therapeutic, follow-up and monitoring strat-
egies may have the potential to improve survival [3].
Several studies in oral carcinogenesis point to an
important relationship between aberrant DNA methyla-
tion at the promoter of tumor suppressor genes and
their inactivation [4–9]. DNA methylation is a frequent
epigenetic event that occurs by the addition of a methyl
group (-CH3) to a cytosine (C) situated at a 5′ position
of a guanine (G) in CpG dinucleotides of superior
eukaryotic cells [10, 11]. Genetic and epigenetic events
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can confer competitive advantages to a cell leading to a
cancer phenotype [12, 13], therefore a wide transcrip-
tome analysis revealing the molecular mechanisms
underlying cancer environment is important [14, 15].
The integration of different data sets such as serial ana-
lysis of gene expression (SAGE), expressed sequence tags
(ESTs) and open reading expressed sequence tags (ORES-
TES), provide powerful platforms to evaluate gene expres-
sion data in cancer tissues [16]. The ORESTES data set
was developed by a Brazilian research group during the
Human Cancer Genome Project, yielding more than 1
million sequences representing parts of mRNAs expressed
in different tumors [17]. This technology allowed the ac-
quisition of sequences from the central codifying region of
transcripts by using random primers [18] and was used to
identify differentially expressed genes and several tran-
scriptomes [15, 17, 19–21]. All sequences produced in
these projects are available in public databases.
The Cancer Genome Atlas (TCGA) Research Network
is a multi-institutional consortium focused on the com-
prehensive clinical and molecular profiling of 32 differ-
ent tumor types [22]. Head and neck squamous cell
carcinoma (HNSCC) sample collection from TCGA
data portal contains 528 cases, including samples
from oral cavity, larynx, tonsils, base of tongue, phar-
ynx and lips [22].
The use of gene expression based molecular markers
as tools to improve the understanding of the biological
mechanisms involved in oral cancer carcinogenesis
opens the potential for the discovery of new therapy tar-
gets, better prediction of patient outcome, therapy
choice and surveillance strategies, improving patient
quality of life and survival rates. Thus, in this study, we
used bioinformatics analysis from head and neck ORES-
TES libraries to identify differentially expressed genes in
oral cancer and to investigate whether gene downregula-
tion was a consequence of aberrant methylation. To
validate the findings, we performed the pharmacological
unmasking of OSCC cell lines through their treatment
with a demethylating agent, and analyzed the gene-
expression level of selected genes in patients´ samples.
We further confirmed the results by analyzing methyla-
tion and RNA expression data from the TCGA database.
Methods
In silico analysis of ORESTES data
Downregulated transcripts were selected from ORESTES
data available at the National Center for Biotechnology
Information (NCBI) database. A bioinformatic analysis
generated a list of differentially expressed genes in differ-
ent head and neck squamous cell carcinoma subsites in
comparison to their correspondent normal tissue. The
program BlastN was used to compare the 946,260
ORESTES sequences deposited at NCBI with the 29,529
reference sequences of human genes presented at the
RefSeq database [23]. The best hit of an ORESTES se-
quence with a human gene was selected to define from
which gene this sequence was generated, with no visual
inspection. Only hits with e-values better than 1 × 10− 10
were considered, thus, 570,214 ORESTES were included
in this analysis. Results were then loaded into a rela-
tional database.
Only normal and tumor head and neck ORESTES
libraries were analyzed (see Additional file 1: Table S1)
which were compared by three ways: (1) normal larynx
libraries plus normal hypopharynx libraries were com-
pared with oral cavity tumor library; (2) normal larynx
libraries were compared with larynx tumor libraries; and
(3) normal hypopharynx libraries were compared with
hypopharynx tumor libraries. The Fisher Exact Test was
applied to identify genes differentially expressed and a p-
value < 0.05 was used to consider statistical significance.
Downregulated candidate genes selection
By using available web tools (see Additional file 2: Table
S2), several criteria were applied to define the best
downregulated candidate genes such as: (1) the presence
of CpG island in the promoter region; (2) ESTs expres-
sion evaluation in head and neck tissue; and (3) data
from a literature review. In this last criterion, genes with
biologic functions related to carcinogenesis and those
described as downregulated in other tumors were in-
cluded, while genes previously described as oncogenes
or overexpressed were excluded.
OSCC specimen and control samples
Twenty primary OSCC specimens from patients surgi-
cally treated at the Department of Head and Neck
Surgery, A. C. Camargo Hospital and available at the
Tumor Bank of this institution were included. All tissues
were subjected to intraoperative frozen section evalu-
ation to select necrosis and calcification-free areas and
immediately stored at − 80°C until nucleic acid extrac-
tion. Ten histologically normal oral mucosa samples
were collected from healthy donors undergoing dental
and pre-prosthetic surgeries and were used as control
tissue. Written informed consent was obtained from all
OSCC patients and healthy donors at the time of enroll-
ment and all aspects of this investigation were approved
by the Ethics Committees of A. C. Camargo Hospital
(process number 737/05).
Tumor cell lines
HNSCC cell lines JHU-12, JHU-13, JHU-19, JHU-28 were
kindly provided by Dr. Joseph Califano (Department of
Otolaryngology and Head and Neck Surgery - Jonhs
Hopkins University). FaDu cell line was acquired from
ATCC (American Type Cell Collection – Rockville, MD).
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JHU-12, JHU-13, JHU-19, JHU-28 cell lines were main-
tained in RPMI medium and FaDu in MEM medium, sup-
plemented with 10% fetal bovine serum in the presence of
antibiotics at 37 °C with 5% CO2.
5′-aza-2′-deoxycytidine treatment
To investigate a possible role of epigenetic in the down-
regulation of selected genes, 105 JHU-13 and FaDu cells
were seeded on day 0 and treated with 1 μM of the
demethylating agent 5-aza-dC (Sigma-Aldrich, St. Louis,
MO) for 3, 5 and 7 days. DNA and RNA were extracted
at days 0, 3, 5 and 7 and stored at − 80°C. The level of
gene expression of the genes selected was tested before
and after treatment with the demethylating agent,
following the procedures described next.
RNA extraction and cDNA synthesis
Total RNA from normal and tumor samples was ex-
tracted using the TRIzol Reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocol.
Total RNA from HNSCC cell lines was extracted by
cesium chloride gradient ultracentrifugation method.
Briefly, cells were homogenized in 9 mL of lyses solution
(4 M guanidinium isothiocyanate, 2 mM sodium citrate
pH 7.0; 0.1 M β-mercaptoethanol). The cell lysate was
then transferred to an ultracentrifuge tube with 4 mL of
cesium chloride solution (5.7 M CsCl; 1 M sodium acet-
ate) and submitted to 29,000 rpm for 20 h at 20°C.
Following centrifugation, the RNA pellet was dissolved
in 100 μL of RNAse-free water. All extracted RNA
samples were quantified in the spectrophotometer
NanoDrop-ND 1000 (Thermo Scientific, Wilmington,
DE) and analyzed by electrophoresis in 1% agarose gel
stained by 0.5 μg/mL ethidium bromide.
Two micrograms of template RNA were used for first-
strand cDNA synthesis using oligo (dT) primers and the
reverse transcriptase Superscript III (Invitrogen, Carlsbad,
CA) following manufacturer’s instructions. The cDNA
product was diluted 10 times prior to use. Quality cDNA
control was performed by the amplification of an ACTB
(NM 001101) fragment using forward (5´-CACTGTGTT
G GCGTACAGGT-3′ and reverse primers (5´-TCATC
ACCATTGGCAATGAG-3′). Reactions were carried out
under the following conditions: 94 °C for 2 min, followed
by 35 cycles at 94 °C for 30 s, 58 °C for 45 s, 72 °C for 45 s
and 72 °C for 7 min. PCR products were evaluated by
electrophoresis in 1% agarose gel stained with 0.5 μg/mL
ethidium bromide.
Validation of mRNA expression changes in HNSCC cell
lines by RT-PCR
The expression level of ten genes (CA3, FHL1, HMGN4,
FSTL1, NFE2L1, SAR1B, C9orf64, ANXA6, WDR26, CC
N1) was evaluated by Reverse Transcription PCR (RT-
PCR) in five HNSCC cell lines. Primer sequences, ampli-
con sizes, MgCl2 concentration and annealing tempera-
tures are available in Table 1.
Real-time quantitative RT-PCR (qRT-PCR) analysis
To validate the expression profile data from HNSCC cell
lines in clinical samples, mRNA levels of the selected
candidate genes CA3 and FHL1 were tested by qRT-
Table 1 Primer sequences, product size, MgCl2 concentration and annealing temperatures used in RT-PCR analyses
Gene Primer sequence (5′-3′) Product size (bp) MgCl2 (mM) Annealing temperature (°C)
CA3 F: TGAAGCAGCGCGATGGGAT
R: GTCAGAGCTCACGGTCATGGGC
260 2 66
FHL1 F: CCGCTTCTGGCATGACACCT
R: ACGGTCCCCTTGTACTCCACG
189 2 66
ANXA6 F: -CCGGCACAGATGAAAAGGCTC
R: TTCTCCTCCCTCCTCACGATGC
191 2 66
WDR26 F: TGCCAATTGCGGAGCTGACA
R: CGTCTGCTCCAAATTCACCATCAA
196 2 66
HMGN4 F: CCTTCCCTCGCCTTCCTGTTCC
R: TGTCCTCCTCACGCTGTTCCTGG
182 1 66
C9orf64 F: AGGCTCTTTTCTCAACTGCGTCCGT
R: AGCAGCCATCTCCTTTTCCTTCCA
191 2 66
FSTL1 F: CCCAGACCCAGACAGAGGAGGAG
R: ACTGGTGATTTGGCGACTGTAGCA
203 2 66
CCN1 F: GCAATTCAGAGGATCCATG
R: GGTGTGCTTGAGGGGACGGTAG
220 3 55
SAR1B F: ACCACGAAAGGCTGTTAGAGTCAAAA
R: AACCAAACATCTCTCGCAACCTCTC
146 2 66
NFE2L1 F: ACGGAACCTGCTAGTGGATGGAGA
R: CTGTTATGCTGGAAATGTCTGCTGGA
167 1 70
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PCR on 20 OSCC cases and 10 normal oral samples. All
qRT-PCR analyses were performed on an ABI 7000
Sequence Detection System (Applied Biosystems, Foster
City, CA) using SYBR Green (Applied Biosystems, Faster
City, CA) for detection. Tests for optimal annealing con-
ditions, as well as melting curve analysis to confirm
amplification specificity were conducted for each set of
gene-specific primers.
The amplification reactions were carried out using
2 μL of cDNA template in a final volume of 20 μL con-
taining: 1 U of Platinum Taq DNA Polymerase (Invitro-
gen, Grand Island, NY), 1X polymerase buffer, 2 mM
MgCl2, 200 μM of each dNTP, 20 pmol of each primer,
5% DMSO and 0.2 μL of SYBR Green I (working dilu-
tion 1:100; Applied Biosystems, Faster City, CA). The
standard amplification protocol consisted of an initial de-
naturation step for 2 min at 95 °C, followed by 40 amplifi-
cation cycles at 95 °C for 15 s, annealing at 68 °C (CA3) or
72 °C (FHL1) for 30 s and extension at 72°C for 30 s.
Experiments were performed in triplicates and mean
values were used for gene expression calculations. The
relative gene expression level was estimated using the 2-
ΔΔCt method [24]. Each sample data was normalized on
the basis of the expression of three reference genes
RPLO, PPIA and TBP [21]. The results were expressed
as n-fold differences in the relative expression of the ref-
erence genes in tumor and the normal samples. A gene
was considered downregulated when the expression level
was below the arbitrary cut-off adopted (2-fold change
downregulation).
In silico TCGA data analysis
We decided to further validate the results from the
selected genes by analyzing the TCGA data on gene ex-
pression and methylation available for HNSCC (UNC_Il-
luminaHiSeq_RNASeqV2 for RNA sequencing data;
JHU-USC_HumanMethylation450, for DNA methylation
data; and Biotab for clinical data). The data from 14 nor-
mal and 312 OSCC samples were all obtained from the
TCGA data portal (http://www.cbioportal.org/study?-
id=hnsc_tcga#summary). Samples included are described
in Additional file 3: Table S3. Methylation data for both
genes analyzed were targeted by multiple probes, but
only mean β-values for each gene were used in statistical
analysis. Expression and methylation differences between
tumor and normal OSCC samples were tested with inde-
pendent t-test at 5% significance level. Pearson’s correl-
ation test was performed for CA3 and FHL1 mRNA
expression and methylation, at 5% significance level. For
the heatmap graphical representations, CA3 and FHL1
mRNA expression levels were dichotomized at 250 and
2300 (normalized counts), respectively. These values
were chosen arbitrarily in order to best maximize the
capacity of distinction between OSCC and healthy
subjects, based in the box-plot graphs presented in Fig. 4.
Statistical analyses were performed in SPSS v19. Graph-
ical heatmap representations were constructed with
heatmap3 package of R statistical software [25, 26].
Results
Selection of downregulated genes in HNSCC
The program Blastn was run for 946,260 ORESTES
against the RefSeq database of human genes, resulting in
570,214 ORESTES selected in this analysis. Comparisons
of normal and tumor head and neck ORESTES libraries
using Fisher’s Exact Test generated a list with 75 differ-
entially expressed genes (64 downregulated and 11 up-
regulated genes). The 64 downregulated genes are listed
in Additional file 4: Table S4 and the accession numbers
for the libraries used are listed in Additional file 5: Table
S5. Thirty of these candidates presented CpG islands at
their promoter sites and their expression in head and
neck was validated by using the Virtual Northern tool
from SAGE Anatomic Viewer - Cancer Genome Anat-
omy Project (SAV-CGAP). This analysis confirmed 24
candidates as downregulated in HNSCC. After a review
of the literature data, genes with biologic functions related
to carcinogenesis or described as downregulated in other
tumors were selected. By the end, we were able to select 10
genes for the assessment of gene expression in HNSCC cell
lines (CA3, FHL1, ANXA6, WDR26, HMGN4, C9orf64,
FSTL1, CCN1, NFE2L1 and SAR1B).
Evaluation of selected genes expression in head and neck
cell lines
Due to the scarcity of RNA obtained from many samples
evaluated in the following steps and the high number of
genes selected, it would be virtually impossible to evalu-
ate all possible candidate-genes in all samples. Therefore,
we performed a first assessment of the expression of
these 10 selected genes in cell lines and picked up only
the most promising candidates to be evaluated in further
experiments with patients’ samples. The results showed
that CA3 was expressed in four of the cell lines evalu-
ated, whereas no mRNA was detected in the JHU-13
cell line, suggesting that this gene is downregulated in
this cell line. FHL1 showed reduced mRNA expression
only in FaDu cell line, being expressed in the other cell
lines evaluated. The eight remaining genes (ANXA6,
WDR26, HMGN4, C9orf64, FSTL1, CCN1, SAR1B and
NFE2L1) were expressed in all five HNSCC cell lines
evaluated (Fig. 1).
Validation of mRNA expression in OSCC samples by qRT-
PCR
After observing the CA3 and FHL1 downregulation in
HNSCC cell lines, we sought to test the expression level
of these genes in 20 OSCC samples. Clinical and
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pathological data of the 20 OSCC patients enrolled in
this study are as follows: the mean age was 59.4 years,
80% of the patients were male, 70% were tobacco users,
60% had advanced stage tumors (II-IV) and 75% of the
tumors were in the oral tongue followed by 20% in the
floor of the mouth and 5% in the alveolar ridge. Seventy-
five percent (15/20) of the samples showed downregula-
tion of FHL1 while CA3 was downregulated in 60% (12/
20) of the samples (Fig. 2). The Mann-Whitney test was
performed to assess the difference between the ex-
pression levels of these two genes between OSCC and
normal samples. Results showed a statistically signifi-
cant difference between these two groups for FHL1
(p = 0.0366), but not for CA3 (p = 0.1528).
In silico TCGA validation
To validate the results obtained with the 20 OSCC pa-
tient samples and cell lines in a larger cohort, we ana-
lyzed publicly available TCGA data of DNA methylation
and mRNA expression (Figs. 3 and 4). Supervisionized
heatmap (by sample type) of CA3 methylation β-values
showed a clear separation in samples, where normal
samples were frequently hypomethylated for most of the
probes (Fig. 3). FHL1 methylation heatmap did not show
a clear separation (Fig. 3). Statistical analysis of mean
methylation β-values supports these observations, for
CA3 and FHL1 (p < 0.0001 and p = 0.055, respectively;
Fig. 4a and c). In addition, mRNA expression values also
showed a clear discrimination of normal and tumoral
samples, where most of the tumor samples presented
downregulation of both CA3 and FHL1 genes (p < 0.0001
– Fig. 4b and d). Pearson’s correlation analysis showed a
significant correlation between mRNA expression and
mean methylation for the CA3 gene (r = − 0.176; p = 0.001
– Fig. 4b) and a trend on this correlation for FHL1
(r = − 0.100; p = 0.071 – Fig. 4d). Although statistical
analysis of FHL1 methylation was not significant, all
results toghether suggest that expression of CA3 and
FHL1 is probably regulated by methylation.
Expression evaluation after 5′-aza-dC treatment
In order to evaluate if methylation may contribute to the
silencing of gene CA3 and FHL1, the cell lines JHU-13
and FaDu were submitted to 5′-aza-dC treatment. RT-
PCR showed that CA3 downregulation in JHU-13 cell
line at day 0 (without 5′-aza-dC treatment) was reverted
by 3-day treatment with 1 μM of 5′-aza-dC and the gene
expression was gradually recovered until day 7 of treat-
ment (Fig. 5a). FHL1 gene was not expressed in FaDu
cell line, but the 3-day treatment with 1 μM of 5′-aza-
dC restored the gene expression (Fig. 5b). Once again,
these results suggest that expression of CA3 and FHL1
could be regulated by methylation of the promoter
region.
Discussion
A detailed analysis from ORESTES libraries data may be
useful on the identification of differentially expressed
genes [12, 15, 21, 27]. Based on this concept, this
Fig. 1 RT-PCR analysis of CA3, FHL1, ANXA6, WDR26, HMGN4, C9orf64,
FSTL1, CCN1, SAR1B and NFE2L1 expression in five HNSCC cell lines
(represented above). Note, the expression of CA3 is not detectable in
JHU-13 (O13) cell line and FHL1 is downregulated in FaDu cell line.
Legend: (Ladder) 100 bp DNA Ladder (Invitrogen). + positive control
(SW 480 tumor cell line) and NTC (no template control). ACTB mRNA
was used to evaluate quantity in each RT-PCR reaction
Fig. 2 Gene expression profile of FHL1 and CA3 in 20 OSCC samples
and 10 histologically normal oral mucosa samples. The Y-axis shows the
log2 fold-change downregulation of the relative expression (2-ΔΔCt). The
dotted line indicates the cut-off adopted (2-fold downregulation)
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Fig. 3 In silico TCGA validation of mRNA expression and methylation data. Heatmap analysis from TCGA data for methylation status (β-values)
and mRNA expression of CA3 and FHL1 genes in normal and OSCC samples. The black vertical line divides normal from tumor samples
Fig. 4 In silico TCGA evaluation of methylation status and mRNA expression of CA3 and FHL1. a and b boxplots show mean methylation β-values
in normal and tumor tissues, for CA3 and FHL1 genes, respectively. c and d boxplots show mRNA expression distributions, in normal and tumor
tissues, for CA3 and FHL1 genes, respectively. Statistical p values denote Student’s ttest between normal and OSCC samples. e and f show
Pearson’s correlation of mean methylation β-values and mRNA expression, for CA3 and FHL1 genes, respectively
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technology was used hereby to identify new candidate
genes related to oral carcinogenesis. In silico analysis of
ORESTES sequences allowed the identification of 75 dif-
ferentially expressed genes in the head and neck site,
with 64 genes being downregulated. Reis and colleagues
[12] conducted a detailed genome mapping analysis of
134,495 ORESTES derived from non-tumor and tumor
tissues of the head and neck and thyroid sites. This ana-
lysis revealed preferentially expressed genes at the head
and neck site as a source of tissue-specific candidate
markers for HNSCC.
Twenty-four of the selected genes presented CpG
islands in their promoters and had the downregulated
expression confirmed by the analysis of head and neck
EST public data, reinforcing the idea that ORESTES is a
valuable tool to identify differentially expressed genes.
According to Strausberg and colleagues [16] the integra-
tion of different molecular data sets provides a powerful
platform for surveying a wealth of cancer gene expres-
sion data in cancer tissues and contributes to the devel-
opment of new strategies of detection, diagnostic and
treatment of this disease. A literature search on the
biologic process of the proteins encoded by these 24
genes allowed the selection of 10 downregulated genes
to continue in the subsequent analysis. The importance
of the experiments in assessing the expression of new
candidates is justified by the scarcity of information
about genes involved on the molecular events of oral
carcinogenesis. RT-PCR analysis showed that eight of
these genes presented normal expression in the five
HNSCC cell lines evaluated. On the other hand, two
genes, CA3 and FHL1, were downregulated in JHU-13
and FaDu cell lines, respectively. The evaluation of the
expression level of these two genes in OSCC samples by
qRT-PCR and in a series of cases and controls from
TCGA, demonstrated that FHL1 and CA3 were also
downregulated in patients´ samples.
Although some differences in the gene expression pro-
file is expected between different subtypes of the head
and neck, Chung and colleagues identified 4 different
molecular subtypes of HNSCC using patterns of gene
expression which were not related to the distinct sub-
sites evaluated (tumors from the oral cavity, oropharynx,
hypopharynx and larynx, moreover and normal tissue
samples from tonsils). In this study the authors showed
that, even though the tumors were from different
subsites, the differential gene expression profile did not
correlated with tumor subsites but with different
molecular and histological features such as EGFR-
pathway signature, mesenchymal-enriched subtype, nor-
mal epithelium-like subtype, and a subtype with high
levels of antioxidant enzymes [28]. In spite of that, we
do believe that one potential bias of the gene selection
strategy adopted in this study was the use of normal lar-
ynx and hypopharynx libraries as a control to compare
with oral cancer libraries. Ideally, normal oral cavity
tissue should be used in this comparison, however,
ORESTES libraries from this subsite were not available
in the database. Another putative bias could be the use
of cell lines originated from different head and neck sub-
sites during the selection of candidate genes. This step
was necessary to identify markers with low expression
likely due to epigenetically silencing in tumor cells to be
tested in the tumor samples. These strategies may have
limited our success in selecting all good candidates for
tumor suppressor genes and also allowed the choose of
some false positive candidates. During the validation
process, we avoid this issue comparing oral cavity tissues
from tumor and normal mucosa from healthy donors,
however, all data here presented should be further vali-
dated with larger dataset containing normal and tumors
samples from the oral cavity.
According to previous studies, the most frequent
targets for methylation events are the CpG islands
situated at gene promoter regions [7]. It is well known
that abnormal CpG islands methylation can efficiently
repress the transcription of specific genes and act as one
of the “hits” in the two-hit Knudson hypothesis of tumor
generation [29–31]. Several authors have pointed to a
relationship between DNA methylation of tumor sup-
pressor genes such as p16, DAPK and MGMT and the
Fig. 5 RT-PCR assay for CA3 and FHL1 expression analysis after 5'-
aza-dC treatment with 1 μM for 7 days. a Expression levels of CA3 in
JHU-13 cell line. Note the gradative increase of CA3 expression from 3
to 7 days; b Expression levels of FHL1 in FaDu cell line. Note that FHL1
expression was restored at the third day of treatment. ACTB expression
was used to evaluate the load quantity in each well. + positive control
(HCT tumor cell line) and – negative control (without DNA)
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development and progression of head and neck cancers,
including oral cancer [32–39]. We therefore reasoned
whether aberrant methylation in promoter sites could be
the cause of the downregulation observed in the genes
selected from the HNSCC ORESTES libraries and
started checking for this relationship using in vitro and
in silico models. To answer that, we performed the
pharmacological unmasking of these cell lines through
their treatment with a demethylating agent and observed
an upregulation of these genes in the treated cell lines.
In silico analysis of TCGA data for normal and OSCC
samples showed similar results, with clear-mirrored
methylation/expression profiles for both CA3 and FHL1
genes. These results reinforced the data, initially ob-
tained from the ORESTES analysis.
The CA3 gene (carbonic anhydrase III) is a member of
a multigene family that encodes carbonic anhydrase
isozymes that catalyze the reversible hydration of carbon
dioxide to form carbonic acid [40, 41]. Downregulation
of this gene was observed in human hepatocelular
carcinoma [42] and, according to these authors, the rela-
tionship between CA3 and the response to oxidative
stress suggests a role of this gene as a possible mediator
of apoptosis or programmed cellular death.
The protein encoded by FHL1 (Four-and-a-Half LIM-
domains 1) seems to act as a transcriptional factor, and
to be associated to focal adherence and intercellular
junctions [43]. FHL1 expression was found downregu-
lated in melanoma and leukemia cell lines [44]. Immu-
nohistochemistry analysis revealed the absence of FHL1
expression in astrocitoma, breast carcinoma, renal car-
cinoma, hepatocarcinoma, pulmonary adenocarcinoma,
prosthatic carcinoma and melanoma tumor samples
compared to their corresponding normal tissues [45].
According to these authors, due to its ability in inhibit-
ing specific aspects of tumor cellular growth, FHL1
could have a tumor suppressor activity [45].
The identification of hypermethylated genes in cancer
is extremely important, since silencing confers benefits
to the survival of these cells, contributing to a neoplastic
phenotype and tumor progression, through the accumu-
lation of genetic and epigenetic hits [11]. In the present
study, the treatment of JHU-13 and FaDu cell lines with
the demethylating agent 5-aza-2′-deoxycytidine was able
to restore CA3 and FHL1 expression, possibly showing a
link between CA3 and FHL1 downregulation and aber-
rant methylation in their promoter sites and a role of
methylation in the regulation of these two genes.
Moreover, a recently published study found a
significant association of FHL1 downregulation and its
promoter methylation in OSCC cell lines and tumor
samples, also suggesting that inactivation of the FHL1
in OSCCs is through DNA methylation of the pro-
moter region [46].
Conclusion
In conclusion, our results showed that the downregu-
lation of CA3 and FHL1 data observed in silico were
validated in HNSCC cell lines and OSCC samples and
also suggests that expression of CA3 and FHL1 could
possibly be regulated by methylation having an im-
portant role in the oral carcinogenesis. Moreover,
these results warrant further studies for the evaluation
of the gene expression and methylation profile of
CA3 and FHL1 in larger number of samples with
clinical and demographic data available to allow the
investigation of relevant associations with patient
outcome.
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